NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results

Impact · against what's priced in

NTHI is a significant positive catalyst as the company reports Phase 2a results for NEO100 that substantially exceed historical benchmarks for progression-free survival. The combination of a strong clinical signal and an existing $75 million ATM facility improves the company's ability to fund subsequent development phases.

NTHI+0.70: No priced-in read yet

NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results

What matters in this story

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results

What matters in this story

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

How each ticker is affected

Track these names every morning.

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

Investors pivot to defensive stocks as markets enter a ‘state of alert'

ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026

NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results

What matters in this story

Next reads from the same story arc

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results

What matters in this story

Next reads from the same story arc

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

How each ticker is affected

Track these names every morning.

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2026 Financial Results

Investors pivot to defensive stocks as markets enter a ‘state of alert'

ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026